![Page 1: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/1.jpg)
الرحيم الرحمن ا بسم
1
![Page 2: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/2.jpg)
Should anticoagulation be resumed after cerebral hemorrhage?
An everyday story
2
Moataz Fatthy MSc
• .
![Page 3: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/3.jpg)
3
![Page 4: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/4.jpg)
AGENDA…
• Rationale
• Risk factor
• Risk Stratification
• Complications
• Management
4
![Page 5: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/5.jpg)
5
![Page 6: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/6.jpg)
• The most feared and the most deadly complication of oral anticoagulant therapy
• Anticoagulant therapy during and after anticoagulation-associated ICH.
6
![Page 7: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/7.jpg)
• Unfortunately, little evidence from clinical trials on which to base the decision.
• Nevertheless, the potential benefit of resuming anticoagulation outweighs the considerable risk.
7
![Page 8: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/8.jpg)
Please pick your poison (Franklin michota , MD)
8
![Page 9: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/9.jpg)
• narrow therapeutic window• vary considerably in dose-
response from patient to patient
• subject to significant interactions with other drugs and with foods.
• monitored with laboratory testing
• good patient compliance
• patient education is essential.
9
![Page 10: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/10.jpg)
• Warfarin has a striking effect on the incidence and outcomes of ICH.
• While the overall incidence of ICH in the general population is approximately 25 per 100,000 person-years
• The incidence in patients on warfarin is exponentially higher, at 2 to 3 per 100 per year, and appears to be increasing.
10
![Page 11: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/11.jpg)
• In addition, once ICH occurs, the risk of death is up to twice as high in those on warfarin
• The bulk of this effect is likely due to a higher risk of ongoing bleeding after the event.
11
![Page 12: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/12.jpg)
12
![Page 13: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/13.jpg)
13
![Page 14: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/14.jpg)
Risk factors for intracerebral hemorrhage during warfarin anticoagulation
Firmly established risk factors
• Advancing age (especially >75 years)
• Hypertension (especially systolic blood pressure >160 mmHg)
• History of cerebrovascular disease
• Intensity of anticoagulation
Possible risk factors • Concomitant use of aspirin
• Cerebral amyloid angiopathy
• Asian or Mexican-American ethnicity
• Tobacco smoking
• Heavy alcohol consumption
• Leukoaraiosis detected by brain CT/MRI
• Microbleeds by T2*-weighted MRI
14
![Page 15: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/15.jpg)
15
![Page 16: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/16.jpg)
• A population-based study has reported a four-fold increase in the incidence of warfarin-associated ICH during the 1990s due to the increasing use of warfarin in elderly patients
• Antiplatelet therapy with aspirin increases ICH risk by about 40 percent
16
![Page 17: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/17.jpg)
• Dual antiplatelet therapy with aspirin plus clopidogrel increases the risk of ICH twofold compared with aspirin
• Combining adjusted-dose warfarin with aspirin appears to double the ICH risk compared with similar intensities of warfarin anticoagulation without aspirin.
17
![Page 18: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/18.jpg)
18
![Page 19: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/19.jpg)
Suggested patient risk stratification for arterial or venous thromboembolism
19
![Page 20: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/20.jpg)
INDICATION FOR VITAMIN K ANTAGONIST
MECHANICAL HEART VALVE
ATRIAL FIBRILLATION
VENOUS THROMBOEMBOLISM
High risk
Any mitral valve prosthesisOlder prosthetic aortic valveRecent stroke or transient ischemic attack (within 6
months(
CHADS2 score ≥ 5Recent stroke or transient ischemic attack (within 3 months(Rheumatic valvular heart disease
Recent event (within 3 months(Severe thrombophilia (low protein C, protein S, or antithrombin level; antiphospholipid antibody syndrome; multiple
abnormalities(
Moderate risk
Bileaflet aortic valve prosthesis and one of the following:Atrial fibrillationPrior stroke or transient ischemic attackHypertensionDiabetesCongestive heart failureAge over 75
CHADS2 score 3 or 4Prior stroke or transient ischemic attack
Venous thromboembolic event in the past 3 to 12 monthsNonsevere thrombophilic conditions (eg, heterozygous factor II mutation(Recurrent venous thromboembolismActive cancer (treated within 6 months, or
palliative treatment(
Low risk
Bileaflet aortic valve prosthesis without atrial fibrillation, and with no other stroke risk factors
CHADS2 score ≤ 2 and no prior stroke or transient ischemic attack
Single venous thromboembolic event > 12 months ago and no other risk factors
20
![Page 21: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/21.jpg)
INDICATION FOR VITAMIN K ANTAGONIST
MECHANICAL HEART VALVE
ATRIAL FIBRILLATION
VENOUS THROMBOEMBOLISM
High risk
Any mitral valve prosthesisOlder prosthetic aortic valveRecent stroke or transient ischemic attack (within 6
months(
CHADS2 score ≥ 5Recent stroke or transient ischemic attack (within 3 months(Rheumatic valvular heart disease
Recent event (within 3 months(Severe thrombophilia (low protein C, protein S, or antithrombin level; antiphospholipid antibody syndrome; multiple
abnormalities(
21
![Page 22: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/22.jpg)
INDICATION FOR VITAMIN K ANTAGONIST
MECHANICAL HEART VALVE
ATRIAL FIBRILLATION
VENOUS THROMBOEMBOLISM
Moderate risk
Bileaflet aortic valve prosthesis and one of the following:Atrial fibrillationPrior stroke or transient ischemic attackHypertensionDiabetesCongestive heart failureAge over 75
CHADS2 score 3 or 4Prior stroke or transient ischemic attack
Venous thromboembolic event in the past 3 to 12 monthsNonsevere thrombophilic conditions (eg, heterozygous factor II mutation(Recurrent venous thromboembolismActive cancer (treated within 6 months, or
palliative treatment(
22
![Page 23: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/23.jpg)
INDICATION FOR VITAMIN K ANTAGONIST
MECHANICAL HEART VALVE
ATRIAL FIBRILLATION
VENOUS THROMBOEMBOLISM
Low risk
Bileaflet aortic valve prosthesis without atrial fibrillation, and with no other stroke risk factors
CHADS2 score ≤ 2 and no prior stroke or transient ischemic attack
Single venous thromboembolic event > 12 months ago and no other risk factors
23
![Page 24: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/24.jpg)
24
![Page 25: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/25.jpg)
Extracranial bleeding leads to death or disability in only 3% of cases
Intracranial bleeding such as ICH leads to death or disability 76% of cases
25
![Page 26: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/26.jpg)
Higher risk of expansion
26
![Page 27: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/27.jpg)
• Unfortunately, continued bleeding is common after ICH.
• In patients In warfarin-associated ICH, up to 50% of patients who present within 3 hours of symptom onset, 25% of hematomas expand more than 30% over the first hour, and another 12% expand this amount over the next 24 to 48 hours or may be longer.
• Over 70% of patients presenting acutely develop at least some amount of expansion within 24 hours.
27
![Page 28: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/28.jpg)
Higher risk of expansion
• A large hematoma volume on presentation
• Early presentation, especially within 3 hours (??undergo computed tomography (CT( while still bleeding(
• Higher INR is a significant predictor, not just of higher risk, but also of a more delayed expansion.
• Certain radiographic findings indicate higher risk. One is the “spot sign,” ie, contrast extravasation after contrast-enhanced CT.
• Apparently, the more spots present, and the denser the contrast, the greater the risk “spot-sign score”
28
![Page 29: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/29.jpg)
The “spot sign” (arrow), contrast extravasation after contrast-enhanced computed tomography, is associated with a high risk of hematoma expansion.
GOLDSTEIN J N , GREENBERG S M Cleveland Clinic Journal of Medicine 2010;77:791-799
![Page 30: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/30.jpg)
30
![Page 31: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/31.jpg)
In the acute phase..
?In the chronic phase..
?
31
![Page 32: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/32.jpg)
In the acute phase..
• how does the risk of further bleeding (hematoma expansion) compare with the short-term risk of thromboembolism?
In the chronic phase..
• how does the risk of recurrent hemorrhage compare with the excess risk of thromboembolism if the patient does not resume anticoagulation therapy?
32
![Page 33: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/33.jpg)
Acute phase management
• Anticoagulant reversal should be the primary consideration in the first 24 hours
Heparin or LMWH is recommended
72 hours after ICH is diagnosed
Not underweight (< 50 kg),
Normal renal function (creatinine clearance > 30 mL/minute/1.73 m2)
Normal platelet function.
Does not have coagulopathy.
warfarin-related ICH has concomitant DVTor PE (ie, < 4 weeks old), then caval interruption therapy would be indicated.
33
![Page 34: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/34.jpg)
Acute phase management
• Anticoagulant reversal should be the primary consideration in the first 24 hours
Lines of reversal
Vitamin K 5 to 10 mg intravenously
Prothrombin complex concentrates 10 to 50 U/kg
Recombinant factor VIIa 40 to 80 μg/kg
Fresh frozen plasma 10 to 50 U/kg.
34
![Page 35: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/35.jpg)
There are few relevant guidelines for the reversal of anticoagulation in patients with AAICH, and expert opinion on this subject differs
35
• PCC, recombinant factor VIIa, or fresh frozen plasma given with intravenous vitamin K were advocated in the 2008 American College of Chest Physicians Guidelines for patients with life-threatening bleeding such as intracranial hemorrhage
![Page 36: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/36.jpg)
There are few relevant guidelines for the reversal of anticoagulation in patients with AAICH, and expert opinion on this subject differs
36
• Replacement of the vitamin K-dependent factors to correct the INR and the administration of intravenous vitamin K. PCCs were considered a reasonable alternative to FFP. Recombinant factor VIIa was not routinely recommended as a sole agent for reversal
![Page 37: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/37.jpg)
• Other guidelines have suggested using various combinations of vitamin K, FFP, PCC, and recombinant factor VIIa
• PCC preparations are not readily available in emergency departments at most United States hospitals; their use is often restricted to hematology specialists, reducing their immediate availability.
37
![Page 38: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/38.jpg)
Chronic phase management
Evaluations of patients for their risk of thrombosis in light of their original indication for oral anticoagulant therapy.
The risk of ICH is related to the intensity of anticoagulation, a lower target international normalized ratio may be the best compromise, depending on the patient.
Alternatively, antiplatelet therapy alone may offer some benefit with less risk of ICH
38
![Page 39: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/39.jpg)
Whether and when to resume anticoagulation ?
• Old Dilemma
• A new trend
39
![Page 40: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/40.jpg)
Old Dilemma
• ICH in patients with atrial fibrillation, the risk of thromboembolism would need to exceed 7% per year to justify restarting anticoagulation after deep ICH,and no risk level was high enough to justify restarting anticoagulation after lobar ICH.
• The American Heart Association comments that for nonvalvular atrial fibrillation, long-term anticoagulation should be avoided after spontaneous lobar ICH, but that antiplatelet agents may be considered.
• The decision to restart anticoagulation may also be a function of whether the underlying risk factor is a temporary or long term one .
40
![Page 41: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/41.jpg)
Old Dilemma
Clearly, the risk is high on the first day, but small after the first few days.
41
• A history of embolic stroke with atrial fibrillation, should be restarted on warfarin after 10 to 14 days, depending on the risk of thromboembolism and ICH recurrence.
![Page 42: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/42.jpg)
Old Dilemma
42
• The American College of Chest Physicians recommends starting prophylactic-dose heparin the day after an ICH, with no clear guidance on restarting warfarin.
![Page 43: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/43.jpg)
Old Dilemma
43
• The American Heart Association suggests that, in patients with a very high risk of thromboembolism for whom restarting warfarin is considered, warfarin may be restarted 7 to 10 days after ICH onset.
![Page 44: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/44.jpg)
A new trend
• The decision to resume anticoagulation after anticoagulant-associated intracranial hemorrhage should be based on the risk of rebleeding vs the risk of thrombosis.
• Patients determined to be at high risk of thrombosis and low risk of rebleeding are the best candidates for resuming anticoagulation.
44
![Page 45: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/45.jpg)
INDICATION FOR VITAMIN K ANTAGONIST
MECHANICAL HEART VALVE
ATRIAL FIBRILLATION
VENOUS THROMBOEMBOLISM
High risk
Any mitral valve prosthesisOlder prosthetic aortic valveRecent stroke or transient ischemic attack (within 6
months(
CHADS2 score ≥ 5Recent stroke or transient ischemic attack (within 3 months(Rheumatic valvular heart disease
Recent event (within 3 months(Severe thrombophilia (low protein C, protein S, or antithrombin level; antiphospholipid antibody syndrome; multiple
abnormalities(
Moderate risk
Bileaflet aortic valve prosthesis and one of the following:Atrial fibrillationPrior stroke or transient ischemic attackHypertensionDiabetesCongestive heart failureAge over 75
CHADS2 score 3 or 4Prior stroke or transient ischemic attack
Venous thromboembolic event in the past 3 to 12 monthsNonsevere thrombophilic conditions (eg, heterozygous factor II mutation(Recurrent venous thromboembolismActive cancer (treated within 6 months, or
palliative treatment(
Low risk
Bileaflet aortic valve prosthesis without atrial fibrillation, and with no other stroke risk factors
CHADS2 score ≤ 2 and no prior stroke or transient ischemic attack
Single venous thromboembolic event > 12 months ago and no other risk factors
45
![Page 46: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/46.jpg)
Suggested risk stratification for recurrent intracranial hemorrhage
High risk
Cerebral amyloid angiopathy or lobar intracranial hemorrhage
Microbleeds on magnetic resonance imaging
Moderate risk
Hypertensive vasculopathy or deep intracranial hemorrhage with any of the
following: Normal international normalized ratio at the time the hemorrhage is diagnosed
Patient not compliant with the dosing and monitoring of vitamin K antagonist therapy Patient not compliant with antihypertensive therapy
Low riskHypertensive vasculopathy or deep intracranial hemorrhage in a compliant patient
46
![Page 47: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/47.jpg)
Suggested risk stratification for recurrent intracranial hemorrhage
High risk
Cerebral amyloid angiopathy or lobar intracranial hemorrhage Microbleeds on magnetic resonance
imaging
47
![Page 48: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/48.jpg)
Suggested risk stratification for recurrent intracranial hemorrhage
Moderate risk
Hypertensive vasculopathy or deep intracranial hemorrhage with any of the
following: Normal international normalized ratio at the time the hemorrhage is diagnosed
Patient not compliant with the dosing and monitoring of vitamin K antagonist therapy Patient not compliant with antihypertensive therapy
48
![Page 49: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/49.jpg)
Suggested risk stratification for recurrent intracranial hemorrhage
Low riskHypertensive vasculopathy or deep intracranial hemorrhage in a compliant patient
49
![Page 50: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/50.jpg)
RISK OF ICH RISK OF THROMBOEMBOLISM
High Moderate Low
High Do not resume Do not resume Do not resume
Moderate Individualized approach
Individualized approach
Do not resume
Low Resume Resume Do not resume
50
![Page 51: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/51.jpg)
How to avoid …
• Good control of warfarin intensity and limiting the use of aspirin, will reduce the risk of ICH.
• Blood pressure control is especially important for avoiding ICH. The use of warfarin in elderly patients should go hand in hand with aggressive blood pressure management.
• If patients on long-term warfarin have a history of falls, risk factor screening/intervention program for reducing the risk of falls may be of value.
51
![Page 52: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/52.jpg)
Take home message
• Pick up your poison• ICH is the nightmare• Acute management includes anticoagulant reversal and
should be the primary consideration in the first 24 hours
• Patients determined to be at high risk of thrombosis and low risk of rebleeding are the best candidates for resuming anticoagulation.
• Consider INR control ,BP control, patients with recurrent falls and other anticoagulation methods with higher compliance
52
![Page 53: Resuming anticagulation in intracerebral hemorrhage patients](https://reader030.vdocument.in/reader030/viewer/2022020218/559511691a28ab06108b47a0/html5/thumbnails/53.jpg)
53